Company intelligence / Profile preview
Formycon AG
Munich, Bavaria, Germanyformycon.com ↗
- Ownership
- Public · FYB
- Development stage
- Commercial
01
Overview
Formycon AG is a leading independent developer of high-quality biosimilars, focusing on treatments in ophthalmology, immunology, and other chronic diseases. The company covers the full value chain from pharmaceutical development through clinical trials to regulatory submission. Its products target highly regulated markets such as the EU, US, Canada, Japan, and Australia. The company leverages deep expertise from its scientific team—many of whom have contributed to bringing some of the world’s first biosimilars to market—and aims to broaden patient access globally.
- Therapeutic areas
- ImmunologyOtherOphthalmology
- Modalities
- BiosimilarsMonoclonal antibodies (mAbs) and other protein-based therapeutics
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Financials
- Market cap
- $280M
- Total revenue
- $49.7M
- Enterprise value
- $231.7M
Beyond the preview
Go deeper on Formycon AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Formycon AG.